Cargando…
Antibody and Protein Profiles in Glaucoma: Screening of Biomarkers and Identification of Signaling Pathways
SIMPLE SUMMARY: Glaucoma is a chronic eye disease that is one of the leading causes of blindness worldwide. Currently, the only therapeutic option is to lower intraocular pressure. The onset of the disease is often delayed because patients do not notice visual impairment until very late, which is wh...
Autores principales: | Auler, Nadine, Tonner, Henrik, Pfeiffer, Norbert, Grus, Franz H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698915/ https://www.ncbi.nlm.nih.gov/pubmed/34943212 http://dx.doi.org/10.3390/biology10121296 |
Ejemplares similares
-
Dynamin-like Protein 1 (DNML1) as a Molecular Target for Antibody-Based Immunotherapy to Treat Glaucoma
por: Tonner, Henrik, et al.
Publicado: (2022) -
A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma
por: Tonner, Henrik, et al.
Publicado: (2022) -
Serological Levels of Anti-clathrin Antibodies Are Decreased in Patients With Pseudoexfoliation Glaucoma
por: Beutgen, Vanessa M., et al.
Publicado: (2021) -
Serum and Antibodies of Glaucoma Patients Lead to Changes in the Proteome, Especially Cell Regulatory Proteins, in Retinal Cells
por: Bell, Katharina, et al.
Publicado: (2012) -
Autoantibody Biomarker Discovery in Primary Open Angle Glaucoma Using Serological Proteome Analysis (SERPA)
por: Beutgen, Vanessa M., et al.
Publicado: (2019)